129 related articles for article (PubMed ID: 34406336)
1. Severe Bilateral Conjunctivitis With Corneal Limbal Infiltrates Associated With Dupilumab Treatment.
Curtis R; Rullo J
JAMA Ophthalmol; 2021 Aug; 139(8):e212012. PubMed ID: 34406336
[No Abstract] [Full Text] [Related]
2. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
3. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
Agnihotri G; Shi K; Lio PA
Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab-Induced Follicular Conjunctivitis.
Shen E; Xie K; Jwo K; Smith J; Mosaed S
Ocul Immunol Inflamm; 2019; 27(8):1339-1341. PubMed ID: 30335586
[No Abstract] [Full Text] [Related]
5. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
Hayama K; Fujita H
Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
[No Abstract] [Full Text] [Related]
6. Cyclosporine 0.1% (Ikervis
Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ
Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
8. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
[TBL] [Abstract][Full Text] [Related]
9. Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
Kido-Nakahara M; Onozuka D; Izuhara K; Saeki H; Nunomura S; Takenaka M; Matsumoto M; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Saito R; Okano T; Miyagaki T; Aoki N; Nakajima K; Ichiyama S; Tonomura K; Nakagawa Y; Tamagawa-Mineoka R; Masuda K; Takeichi T; Akiyama M; Ishiuji Y; Katsuta M; Kinoshita Y; Tateishi C; Yamamoto A; Morita A; Matsuda-Hirose H; Hatano Y; Kawasaki H; Fukushima-Nomura A; Ohtsuki M; Kamiya K; Kabata Y; Abe R; Mitsui H; Kawamura T; Tsuji G; Furue M; Katoh N; Nakahara T
Allergol Int; 2024 Apr; 73(2):332-334. PubMed ID: 38151410
[No Abstract] [Full Text] [Related]
10. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.
Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S
Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238
[TBL] [Abstract][Full Text] [Related]
11. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
12. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS; Ariens LFM; van Luijk C; van der Schaft J; Thijs JL; Schuttelaar MLA; van Wijk F; Knol EF; Balak DMW; van Dijk MR; de Bruin-Weller MS
Br J Dermatol; 2019 May; 180(5):1248-1249. PubMed ID: 30597515
[No Abstract] [Full Text] [Related]
13. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis.
Voorberg AN; den Dunnen WFA; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e64-e66. PubMed ID: 31465590
[No Abstract] [Full Text] [Related]
14. Dupilumab and conjunctivitis: a case series of twenty patients.
Calabrese G; Gambardella A; Licata G; Di Brizzi EV; Alfano R; Argenziano G
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e612-e614. PubMed ID: 33657247
[No Abstract] [Full Text] [Related]
15. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.
Thyssen JP; de Bruin-Weller MS; Paller AS; Leshem YA; Vestergaard C; Deleuran M; Drucker AM; Foelster-Holst R; Traidl-Hoffmann C; Eyerich K; Taieb A; Su JC; Bieber T; Cork MJ; Eichenfield LF; Guttman-Yassky E; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1224-1231. PubMed ID: 31056788
[TBL] [Abstract][Full Text] [Related]
16. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
[No Abstract] [Full Text] [Related]
17. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
[TBL] [Abstract][Full Text] [Related]
18. Pathomechanism of dupilumab-associated inflammatory eye symptoms.
Wohlrab J; Werfel T; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e435-e436. PubMed ID: 31220376
[No Abstract] [Full Text] [Related]
19. Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use.
Jo CE; Georgakopoulos JR; Drucker AM; Piguet V; Yeung J
J Cutan Med Surg; 2020; 24(5):527-528. PubMed ID: 32449620
[No Abstract] [Full Text] [Related]
20. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Treister AD; Kraff-Cooper C; Lio PA
JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
